Chimeric peptide engineered exosomes for dual-stage light guided plasma membrane and nucleus targeted photodynamic therapy

Cheng, Hong; Fan, Jing-Hao; Zhao, Lin‐Ping; Fan, Guijuan; Zheng, Rongrong; Qiu, Xiaozhong; Yu, Xiyong; Li, Shiying; Zhang, Xian‐Zheng

doi:10.1016/j.biomaterials.2019.05.004

Cited by 127 publications

(83 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug distribution in the tumor of the BTZ-NP group was statistically higher than the BTZ solution group. The superior enrichment of the BTZ-NP in the malignant tissue was ascribed to the EPR effects of the nano-drug delivery systems and, would promise profound therapeutic effects [16][17][18][19][20][21][22][23][24].…”

Section: In Vivo Distribution Of the Btz-npmentioning

confidence: 99%

Preparation, characterization and in vitro–in vivo evaluation of bortezomib supermolecular aggregation nanovehicles

et al. 2020

Self Cite

View full text Add to dashboard Cite

Backgrounds: Intolerable toxicity and unsatisfactory therapeutic effects are still big problems retarding the use of chemotherapy against cancer. Nano-drug delivery system promised a lot in increasing the patients' compliance and therapeutic efficacy. As a unique nano-carrier, supermolecular aggregation nanovehicle has attracted increasing interests due to the following advantages: announcing drug loading efficacy, pronouncing in vivo performance and simplified production process. Methods: In this study, the supermolecular aggregation nanovehicle of bortezomib (BTZ) was prepared to treat breast cancer. Results: Although many supermolecular nanovehicles are inclined to disintegrate due to the weak intermolecular interactions among the components, the BTZ supermolecules are satisfying stable. To shed light on the reasons behind this, the forces driving the formation of the nanovehicles were detailed investigated. In other words, the interactions among BTZ and other two components were studied to characterize the nanovehicles and ensure its stability. Conclusions: Due to the promising tumor targeting ability of the BTZ nanovehicles, the supermolecule displayed promising tumor curing effects and negligible systemic toxicity.

show abstract

Section: In Vivo Distribution Of the Btz-npmentioning

confidence: 99%

Preparation, characterization and in vitro–in vivo evaluation of bortezomib supermolecular aggregation nanovehicles

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…39 Their efficacy depends on the efficient transfer of the drugs or complete therapeutic exogenous gene into the nucleus. 40 In recent studies, the nucleus has been commonly used as the site of action for free radicals and heat to cooperate with chemotherapy or gene therapy to improve the antitumor effect, 41 which means transporting photosensitizers or theranostics to the nucleus to produce ROS with potentially damaging effects. 42,43 However, the NDDSs targeting the cancer cell membrane generally only release foreign genes or anticancer agents into the cytoplasm, and then they can only enter the nucleus through free diffusion.…”

Section: Lysosomal Accumulationmentioning

confidence: 99%

Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting

Shi

et al. 2020

Sig Transduct Target Ther

View full text Add to dashboard Cite

Therapeutic efficacy against cancer relies heavily on the ability of the therapeutic agents to reach their final targets. The optimal targets of most cancer therapeutic agents are usually biological macromolecules at the subcellular level, which play a key role in carcinogenesis. Therefore, to improve the therapeutic efficiency of drugs, researchers need to focus on delivering not only the therapeutic agents to the target tissues and cells but also the drugs to the relevant subcellular structures. In this review, we discuss the most recent construction strategies and release patterns of various cancer cell subcellular-targeting nanoformulations, aiming at providing guidance in the overall design of precise nanomedicine. Additionally, future challenges and potential perspectives are illustrated in the hope of enhancing anticancer efficacy and accelerating the translational progress of precise nanomedicine.

show abstract

“…Cheng et al [151], tried a different approach where they functionalised murine exosomes with a "ChiP" consisting of chimeric peptide for targeting both the plasma membrane and the nucleus (by nuclear localisation sequence (NLS)), and protoporphyrin IX (PpIX) as PS. This functionalisation aimed at helping the exosomes anchor onto the cell membranes and enter the cells through endocytosis, to be released into the cytosol by PCI and enter the nucleus by means of the NLS sequence.…”

Section: Nanoparticle-mediated Pci As a Powerful Anticancer Drug Delimentioning

confidence: 99%

Photochemical Internalization for Intracellular Drug Delivery. From Basic Mechanisms to Clinical Research

Jerjes¹,

Theodossiou

Hirschberg

et al. 2020

JCM

View full text Add to dashboard Cite

Photochemical internalisation (PCI) is a unique intervention which involves the release of endocytosed macromolecules into the cytoplasmic matrix. PCI is based on the use of photosensitizers placed in endocytic vesicles that, following light activation, lead to rupture of the endocytic vesicles and the release of the macromolecules into the cytoplasmic matrix. This technology has been shown to improve the biological activity of a number of macromolecules that do not readily penetrate the plasma membrane, including type I ribosome-inactivating proteins (RIPs), gene-encoding plasmids, adenovirus and oligonucleotides and certain chemotherapeutics, such as bleomycin. This new intervention has also been found appealing for intracellular delivery of drugs incorporated into nanocarriers and for cancer vaccination. PCI is currently being evaluated in clinical trials. Data from the first-in-human phase I clinical trial as well as an update on the development of the PCI technology towards clinical practice is presented here.

show abstract

Chimeric peptide engineered exosomes for dual-stage light guided plasma membrane and nucleus targeted photodynamic therapy

Cited by 127 publications

References 49 publications

Preparation, characterization and in vitro–in vivo evaluation of bortezomib supermolecular aggregation nanovehicles

Preparation, characterization and in vitro–in vivo evaluation of bortezomib supermolecular aggregation nanovehicles

Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting

Photochemical Internalization for Intracellular Drug Delivery. From Basic Mechanisms to Clinical Research

Contact Info

Product

Resources

About